1. Service de médecine interne, CHU Hôtel-Dieu, Nantes, France;2. Clinique dermatologique, CHU Hôtel-Dieu, place Alexis Ricordeau, 44093 Nantes cedex 1, France
Abstract:
Many cutaneous adverse events have been identified with recently developed targeted treatments. Some of them are common and specific, like paradoxical psoriasiform eruptions with anti-TNFα, papulopustular eruptions and paronychias with EGFR inhibitors and peculiar hand-foot skin reactions with multitargeted kinase inhibitors sorefenib and sunitinib. Patients treated with these recently available biologics need a careful monitoring.